Faron Pharmaceuticals Share Price | |
---|---|
Price | 98.50 |
Bid | 97.00 |
Ask | 100.00 |
Change | 0.50 (0.51%) |
Volume | 107,836 |
Open | 98.00 |
High | 98.50 |
Low | 98.00 |
Prev. Close | 98.00 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 86.68m |
Market Capitalisation | £85.38m |
Market Size | 750 |
52 Week High | 360.00 |
52 Week High Date | 11-Dec-2023 |
52 Week Low | 89.00 |
52 Week Low Date | 20-Jun-2024 |
# Trades | 23 |
---|---|
Vol. Sold | 17,809 |
Sold Value | £17.38k |
Vol. Bought | 25,564 |
Bought Value | £25.43k |
PE Ratio | -2.841742 |
Earnings | -34.66184 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
20-Jun-24 | 08:07:36 | 90.00 | 43,005 | Unknown* | 97.00 | 100.00 | 38.70k | O Ordinary Delayed publication Historical |
21-Jun-24 | 17:07:31 | 98.50 | 50,000 | Unknown* | 97.00 | 100.00 | 49.25k | O Ordinary Was reported as OTC |
21-Jun-24 | 14:28:19 | 96.155 | 7,000 | Unknown* | 97.00 | 100.00 | 6,731 | O Ordinary Delayed publication |
21-Jun-24 | 14:34:49 | 98.90 | 600 | Buy* | 97.00 | 100.00 | 593.40 | O Ordinary |
21-Jun-24 | 14:13:03 | 97.00 | 5,500 | Sell* | 97.00 | 100.00 | 5,335 | O Ordinary |
21-Jun-24 | 14:10:38 | 98.2142 | 1,500 | Sell* | 97.00 | 100.00 | 1,473 | O Ordinary |
21-Jun-24 | 14:07:39 | 97.3272 | 3,620 | Sell* | 97.00 | 100.00 | 3,523 | O Ordinary |
21-Jun-24 | 13:05:45 | 98.121 | 12,463 | Unknown* | 97.00 | 100.00 | 12.23k | O Ordinary Delayed publication |
20-Jun-24 | 16:30:13 | 85.00 | 40,000 | Unknown* | 97.00 | 100.00 | 34.00k | O Ordinary Delayed publication Historical |
20-Jun-24 | 16:30:13 | 85.00 | -40,000 | Unknown* | 97.00 | 100.00 | -34.00k | O Ordinary Deletion Delayed publication Historical |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
04-Apr-24 | 03-Apr-24 | Placing | Tuomo Pätsi held the position of Non-Executive Director at the time of this trade.Tuomo Pätsi | 1.50 | EUR | 13,333 | 250,980 |
04-Apr-24 | 03-Apr-24 | Placing | Markku Jalkanen held the position of CEO at the time of this trade.Markku Jalkanen | 1.50 | EUR | 33,333 | 2,208,599 |
27-Oct-23 | 12-Oct-23 | Sell | John Poulos held the position of Independent Non-Executive Director at the time of this trade.John Poulos | 382.59 | GBX | 5,000 | 10,000 |
27-Oct-23 | 03-Oct-23 | Sell | John Poulos held the position of Independent Non-Executive Director at the time of this trade.John Poulos | 372.09 | GBX | 5,000 | 10,000 |
31-Aug-23 | 28-Aug-23 | Exercise of Option | John Poulos held the position of Independent Non-Executive Director at the time of this trade.John Poulos | 1.09 | EUR | 20,000 | 20,000 |
We offer a promising immunotherapy candidate with a new target to fight cancer.